227 related articles for article (PubMed ID: 8633501)
1. Eosinophilia in primary biliary cirrhosis.
Yamazaki K; Nakadate I; Suzuki K; Sato S; Masuda T
Am J Gastroenterol; 1996 Mar; 91(3):516-22. PubMed ID: 8633501
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis.
Yamazaki K; Suzuki K; Nakamura A; Sato S; Lindor KD; Batts KP; Tarara JE; Kephart GM; Kita H; Gleich GJ
Hepatology; 1999 Jul; 30(1):71-8. PubMed ID: 10385641
[TBL] [Abstract][Full Text] [Related]
3. Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis.
Nakamura A; Yamazaki K; Suzuki K; Sato S
Am J Gastroenterol; 1997 Dec; 92(12):2245-9. PubMed ID: 9399763
[TBL] [Abstract][Full Text] [Related]
4. [Eosinophilia in primary biliary cirrhosis: regression under therapy with ursodeoxycholic acid].
Wirth HP; Meyenberger C; Altorfer J; Ammann R; Blum HE
Schweiz Med Wochenschr; 1994 May; 124(19):810-5. PubMed ID: 8209204
[TBL] [Abstract][Full Text] [Related]
5. [Transient eosinophilia in primary biliary cirrhosis].
Wirth HP; Heer P; Bertschinger P; Meyenberger C; Ammann R; Altorfer J
Schweiz Med Wochenschr; 1993 Dec; 123(48):2278-83. PubMed ID: 8272802
[TBL] [Abstract][Full Text] [Related]
6. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
[TBL] [Abstract][Full Text] [Related]
7. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
8. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis.
Simko V; Michael S; Prego V
Am J Gastroenterol; 1994 Mar; 89(3):392-8. PubMed ID: 8122652
[TBL] [Abstract][Full Text] [Related]
11. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.
Corpechot C; Carrat F; Bonnand AM; Poupon RE; Poupon R
Hepatology; 2000 Dec; 32(6):1196-9. PubMed ID: 11093724
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
Chen L; Borozan I; Milkiewicz P; Sun J; Meng X; Coltescu C; Edwards AM; Ostrowski MA; Guindi M; Heathcote EJ; McGilvray ID
Liver Int; 2008 Aug; 28(7):997-1010. PubMed ID: 18422935
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
Lee YM; Kaplan MM
Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
[TBL] [Abstract][Full Text] [Related]
15. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis.
Hempfling W; Grunhage F; Dilger K; Reichel C; Beuers U; Sauerbruch T
Hepatology; 2003 Jul; 38(1):196-202. PubMed ID: 12830002
[TBL] [Abstract][Full Text] [Related]
17. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation.
Kim WR; Poterucha JJ; Jorgensen RA; Batts KP; Homburger HA; Dickson ER; Krom RA; Wiesner RH; Lindor KD
Hepatology; 1997 Jul; 26(1):22-6. PubMed ID: 9214447
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
[TBL] [Abstract][Full Text] [Related]
19. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis.
Batts KP; Jorgensen RA; Dickson ER; Lindor KD
Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.
Serfaty L; De Leusse A; Rosmorduc O; Desaint B; Flejou JF; Chazouilleres O; Poupon RE; Poupon R
Hepatology; 2003 Jul; 38(1):203-9. PubMed ID: 12830003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
